A collaborative challenge aims to address the problem of medication adherence by predicting adverse treatment events.
James Costello |
Ensuring patient adherence to medication is an ongoing healthcare problem – and it is exacerbated by drug-related side effects; discontinued use of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) is just one example. Could the problem be improved by predicting adverse treatment events? The Dialogue for Reverse Engineering Assessment and Methodology (DREAM) Challenge was established to encourage wide-scale collaboration to tackle the problem. To learn more, we speak with James Costello, Assistant Professor in the Department of Pharmacology at the University of Colorado Anschutz Medical Campus, who has been involved with DREAM for over 7 years.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!